Redmile Group, LLC

Average Profitability
11.45%
Insider Buys Quantity
48
Insider Buys Sum
$563.63M
Insider Sells Quantity
9
Insider Sells Sum
$23.36M

Insider Activity of Redmile Group, LLC

According to the SEC Form 4 filings, Redmile Group, LLC, being in a position of

  1. 10 percent owner at ADC Therapeutics SA,
    оver the last 12 months, has bought 1000000 shares for $2.86M, and sold 25352 shares for $52,479,
    over all time since 2024-07-01, has bought 1000000 shares for $2.86M, and sold 25352 shares for $52,479.

The largest purchase of all time was on 2020-10-14 and amounted to 6882352 shares of Shattuck Labs, Inc. for $119.34M.

The largest sale of all time was on 2016-09-28 and amounted to 2492578 shares of Array Technologies, Inc. for $15.85M.

Biography of Redmile Group, LLC

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
 $3,692,293457
Sells
 $793,136343

Comparison of Insiders on Amount of Buys and Sells

2024-12-20SaleFate Therapeutics, Inc.
FATE
341,633
0.2991%
$1.68$573,943-22.02%
2024-12-20PurchaseFate Therapeutics, Inc.
FATE
397,964
0.3484%
$1.68$668,580-22.02%
2024-12-11PurchaseADC Therapeutics SA
ADCT
10 percent owner
200,000
0.2806%
$3.04$609,000-20.95%
2024-12-04SaleADC Therapeutics SA
ADCT
10 percent owner
25,352
0.0263%
$2.07$52,479-14.98%
2024-12-04SaleShattuck Labs, Inc.
STTK
133,371
0.2728%
$1.25$166,714-3.2%
2024-12-04PurchaseShattuck Labs, Inc.
STTK
133,371
0.2728%
$1.25$166,714-3.2%
2024-07-01PurchaseADC Therapeutics SA
ADCT
10 percent owner
800,000
0.9607%
$2.81$2.25M-23.91%
2024-03-01PurchaseAbsci Corporation
ABSI
director
222,222
0.1982%
$4.50$999,999-24.91%
2023-12-26PurchaseFate Therapeutics, Inc.
FATE
44,630
0.0455%
$3.72$166,024+2.15%
2023-06-29SaleIGM Biosciences, Inc.
IGMS
director
80,423
0.1809%
$9.42$757,585-11.25%
2023-06-29PurchaseIGM Biosciences, Inc.
IGMS
director
80,423
0.1809%
$9.42$757,585-11.25%
2023-04-21PurchaseFate Therapeutics, Inc.
FATE
256,639
0.26%
$6.18$1.59M-27.01%
2023-04-20PurchaseFate Therapeutics, Inc.
FATE
20,000
0.0204%
$5.99$119,800-24.17%
2023-04-14SaleFate Therapeutics, Inc.
FATE
302,339
0.2996%
$5.84$1.77M-24.46%
2023-04-14PurchaseFate Therapeutics, Inc.
FATE
25,700
0.0262%
$6.00$154,200-24.46%
2022-10-13PurchaseZymeworks Inc.
ZYME
10 percent owner
30,481
0.0481%
$5.03$153,435+63.8%
2021-11-02PurchaseEntrada Therapeutics, Inc.
TRDA
10 percent owner
2M
25.0465%
$20.00$40M-53.61%
2021-07-26PurchaseAbsci Corporation
ABSI
director
1.88M
1.7426%
$16.00$30M-63.43%
2021-06-21PurchaseVerve Therapeutics, Inc.
VERV
10 percent owner
2.1M
13.5677%
$19.00$39.9M-7.41%
2021-01-08PurchaseFate Therapeutics, Inc.
FATE
327,485
0.2577%
$85.50$28M-33.06%
Total: 57
Company
About Prismo.proIdeasArticlesPrivacy PolicyTerms of ServiceContact Us
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksStock NewsList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.